NCT04048278

Lidocaine Infusion in Pancreatic Cancer

Recruiting now EARLY_PHASE1 Last updated 3 March 2025

What this trial tests

EARLY_PHASE1 trial testing Lidocaine Hydrochloride in Pancreatic Cancer in 46 participants. Currently enrolling.

Timeline

8 November 2018

Primary endpoint
8 November 2025

1 January 2026

Quick facts

Lead sponsor	University of Illinois at Chicago
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	46
Start date	8 November 2018
Primary completion	8 November 2025
Estimated completion	1 January 2026
Sites	1 location across United States

Drugs / interventions tested

• Lidocaine Hydrochloride (Lidocaine Hydrochloride) — full drug profile →
• Saline Solution for Injection — full drug profile →

Conditions studied

• Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

University of Illinois at Chicago

Who can join

18 and older, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer.

A prospective randomized controlled double blinded trial design will be used for the proposed study.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Repositioning Lidocaine as an Anticancer Drug: The Role Beyond Anesthesia.
   Zhou D, Wang L, Cui Q, Iftikhar R, et al · · 2020 · cited 35× · PMID 32766241 · DOI 10.3389/fcell.2020.00565
2. Local Anesthetics and Recurrence after Cancer Surgery-What's New? A Narrative Review.
   Müller SD, Ziegler JSH, Piegeler T. · · 2021 · cited 19× · PMID 33670434 · DOI 10.3390/jcm10040719
3. Trial watch: local anesthetics in cancer therapy.
   Carnet Le Provost K, Kepp O, Kroemer G, Bezu L. · · 2024 · cited 5× · PMID 38504848 · DOI 10.1080/2162402x.2024.2308940
4. Redefining cancer care: harnessing circulating tumor cells' potential for improved diagnosis and prognosis.
   Janjua D, Chaudhary A, Joshi U, Tripathi T, et al · · 2025 · cited 4× · PMID 40676582 · DOI 10.1186/s12935-025-03883-y
5. Intravenous Lidocaine for Refractory Pain in Patients With Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis: A Multicenter Prospective Nonrandomized Pilot Study.
   Augustinus S, Bieze M, Van Veldhuisen CL, Boermeester MA, et al · · 2024 · cited 3× · PMID 39320960 · DOI 10.14309/ctg.0000000000000760
6. Neuronal mimicry in tumors: lessons from neuroscience to tackle cancer.
   Bloomer H, Dame HB, Parker SR, Oudin MJ. · · 2025 · cited 2× · PMID 39934425 · DOI 10.1007/s10555-025-10249-3
7. Reassessing lidocaine as an electroporation sensitizer in vitro.
   Blažič A, Šmerc R, Polajžer T, Miklavčič D, et al · · 2025 · cited 1× · PMID 40665133 · DOI 10.1038/s41598-025-11695-3
8. Anesthetics and Long Term Cancer Outcomes: May Epigenetics Be the Key for Pancreatic Cancer?
   Mokini Z, Cama A, Forget P. · · 2022 · cited 1× · PMID 36013569 · DOI 10.3390/medicina58081102